Addex Therapeutics (FRA:APE1) GF Score: 7/100 (As of Jul. 11, 2026) — 79% Below Median


FRA:APE1 Addex Therapeutics Ltd FRA:APE1
7 GF Score
Price €4.90
GF Value €1.22
! 6 Warning Signs
View Full Analysis

What is Addex Therapeutics GF Score?

Addex Therapeutics FRA:APE1 +0.41% 7 GF Score is 7 as of Jul. 11, 2026, which is 79% below its 10-year median of 33.00. GuruFocus rates FRA:APE1 with a GF Score™ of 7/100 and a GF Value™ of €1.22. The stock has 6 warning signs investors should review.

Addex Therapeutics has the GF Score of 7, which implies that the company might have Worst future performance potential, or not enough data.

The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.

GF Score takes following five key aspects into consideration:

1. Financial Strength : 0/10
2. Profitability Rank : 0/10
3. Growth Rank : 0/10
4. GF Value Rank : 1/10
5. Momentum Rank : 0/10

Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.

Based on research and backtesting result, GuruFocus believes Addex Therapeutics might have Worst future performance potential, or not enough data.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Addex Therapeutics  (FRA:APE1) GF Score Explanation

Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:

GF Score Performance Potential and All-in-One Screener Examples (1)
91 - 100Highest outperformance potential
81 - 90Good outperformance potential
71 - 80Likely to have average performance
51 - 70Poor future performance potential
0 - 50Worst future performance potential, or not enough data

(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.

Addex Therapeutics GF Score Related Terms

FRA:APE1 vs VRTX, REGN, ALNY: GF Score Comparison

For the Biotechnology subindustry, Addex Therapeutics's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Addex Therapeutics GF Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Addex Therapeutics's GF Score distribution charts can be found below:

* The bar in red indicates where Addex Therapeutics's GF Score falls into.


FRA:APE1
7GF Score
Addex Therapeutics Ltd FRA:APE1
GF Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about GF Score →
What does a GF Score of 7 mean?
Addex Therapeutics (FRA:APE1) has a GF Score of 7 as of Jul. 11, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Addex Therapeutics and its competitors. This is 79% below median its historical median of 33.00. Over the past decade, Addex Therapeutics' GF Score has ranged from 7.00 to 69.00.
Is Addex Therapeutics' GF Score too high?
Addex Therapeutics' current GF Score of 7 is 79% below median its 10-year median of 33.00. Over the past 10 years, this metric has ranged from a low of 7.00 to a high of 69.00. Overall, Addex Therapeutics has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does Addex Therapeutics' GF Score compare to VRTX and REGN?
Addex Therapeutics' GF Score of 7 can be compared against companies in the Biotechnology industry. Historically, Addex Therapeutics' own GF Score has ranged from 7.00 to 69.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Biotechnology company?
A good GF Score depends on the Biotechnology industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Addex Therapeutics and its competitors. Addex Therapeutics's current GF Score is 7, which is 79% below median its own 10-year median of 33.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Addex Therapeutics stock overvalued right now?
Addex Therapeutics (FRA:APE1) has a current GF Score of 7. The stock's GF Value™ is €1.22, compared to a current price of €4.90 — trading 301.6% above its estimated fair value. The current GF Score is 7, which is 79% below median its 10-year median of 33.00. Addex Therapeutics' overall GF Score™ is 7/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Addex Therapeutics (FRA:APE1), the current GF Score is 7 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Addex Therapeutics (FRA:APE1) Overvalued in 2026?

Based on GuruFocus' analysis, Addex Therapeutics stock appears to be overvalued. The current stock price of €4.90 is trading 301.6% above its estimated GF Value™ of €1.22.

Key valuation signals for FRA:APE1:

  • GF Score: 7 (79% below median its 10-year median of 33.00)
  • GF Value™: €1.22 vs. price of €4.90 (301.6% above fair value)
  • GF Score™: 7/100 with 6 warning signs

No single metric tells the full story. See the FRA:APE1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Addex Therapeutics Business Description

Address Chemin des Mines 9, Geneva, CHE, 1202
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.
7GF Score

Get the complete analysis for FRA:APE1

GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.90
Price
€1.22
GF Value